Biocorp Production SA represents values of innovation, quality, and sustainability. The company's corporate philosophy focuses on developing cutting-edge technologies and solutions in the pharmaceutical and medical industries. Biocorp is committed to improving patient care and treatment through its advanced drug delivery systems and connected devices. With a strong emphasis on research and development, Biocorp strives to provide reliable and user-friendly products that enhance patient outcomes. By integrating technology and healthcare, Biocorp Production SA aims to revolutionize the industry and contribute to a healthier future.

Biocorp Production SA is primarily present in several countries and regions worldwide. As a leading company in the biotechnology industry, Biocorp Production SA has established its presence in key markets. Currently, the company operates in multiple countries and regions, including Europe, North America, Asia-Pacific, and Latin America. With its global footprint, Biocorp Production SA has successfully expanded its operations and collaborations to maximize its market reach and serve a diverse customer base.

Biocorp Production SA, a leading stock company, has achieved remarkable milestones in its journey. The company has successfully expanded its product portfolio and entered into strategic partnerships, broadening its market presence. With a focus on innovation, Biocorp has introduced groundbreaking technologies and solutions that have revolutionized the industry. They have also demonstrated consistent financial growth and maintained a strong position in the market. Biocorp Production SA's commitment to quality, customer satisfaction, and sustainability has earned them numerous accolades and recognition within the sector. Through their continuous efforts, Biocorp remains dedicated to driving success and delivering value to its shareholders.

Biocorp Production SA, a leading company in the field of medical devices, has a rich history and background. Established in 2004, Biocorp has been dedicated to developing and manufacturing innovative solutions for drug delivery and patient monitoring. The company focuses on integrating connectivity and customization into its products, catering to the evolving needs of healthcare professionals and patients. With a commitment to quality and technological advancements, Biocorp has gained a strong presence in the global healthcare market. Its expertise in connected devices and partnerships with major pharmaceutical companies have further positioned Biocorp as a reliable and trusted provider in the industry.

The main competitors of Biocorp Production SA in the market include companies such as XYZ Pharmaceuticals, ABC Biotech, and DEF Healthcare.

Biocorp Production SA is primarily active in the pharmaceutical and healthcare industries.

The business model of Biocorp Production SA is centered around the development and manufacturing of innovative medical devices and drug delivery systems. As a leading company in the pharmaceutical industry, Biocorp focuses on providing customized solutions to its clients, such as pharmaceutical companies and healthcare organizations, to enhance patient care and treatment outcomes. Through its cutting-edge technologies and expertise in connected devices, Biocorp aims to improve medication adherence, enable patient monitoring, and streamline the administration of drugs. By offering reliable and user-friendly solutions, Biocorp Production SA aims to establish itself as a trusted provider in the healthcare market.

Biocorp Production KGV ir 41,52.

Biocorp Production KUV ir 5,15.

AlleAktien kvalitātes vērtējums Biocorp Production ir 5/10.

gaidāmā Biocorp Production apgrozījums ir 29,97 milj. EUR.

gaidāmā Biocorp Production peļņa ir 3,72 milj. EUR.

Biocorp Production SA is a company specializing in the manufacture and marketing of products in the field of biotechnology. The company is based in Issoire, France and was founded in 2004. With its expertise and the use of state-of-the-art technologies, the company develops and produces high-quality products in the areas of drug delivery and diagnostics. The main focus is on the development and production of smart drug delivery systems such as Smart Insulin Pens. Under the brand Enject, the company offers a variety of insulin pens that allow for effective, safe, and easy administration of insulin in diabetic patients. The pens can be customized to meet the needs of each individual patient. Another core area of the company is the development of diagnostic systems. Biocorp Production SA offers a diagnostic device called Mallya, which specializes in measuring blood glucose and uric acid levels. The device is easy to use and allows patients to quickly and accurately monitor their blood glucose levels without time-consuming doctor visits. In addition to developing and manufacturing its own products, Biocorp Production SA also collaborates with other companies to develop customized solutions for their specific needs. For example, products such as the insulin pen have been produced for a well-known pharmaceutical company. As a technology company, research and development play an important role in the business of Biocorp Production SA. The company holds several patents on smart injection systems and diagnostic technologies and continuously invests in the development of technologies that bring maximum benefits to its customers and their patients. The company operates internationally and serves both the European and North American markets. It has experienced rapid expansion in recent years and plans to expand its presence in other parts of the world. Overall, Biocorp Production SA offers a wide range of innovative products and services in the field of biotechnology. The company focuses on the development of smart drug delivery systems and diagnostic devices, utilizing state-of-the-art technologies and working closely with other companies to develop customized solutions for its customers.

Biocorp Production izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Biocorp Production vai uzņēmums nedod dividendes.

Biocorp Production ISIN ir FR0012788065.

Biocorp Production WKN ir A14V4G.

Biocorp Production simbols ir ALCOR.PA.

Pēdējo 12 mēnešu laikā Biocorp Production maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Biocorp Production plāno maksāt dividendes 0 EUR apmērā.

Biocorp Production pašreizējā dividendu rentabilitāte ir .

Biocorp Production maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Biocorp Production pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Biocorp Production tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Biocorp Production apmērā 0 EUR, kas tika izmaksāta 9.04.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.04.2025..

Pēdējās dividendes izmaksa notika 9.04.2025..

Gadā 2024, Biocorp Production izmaksāja 0 EUR dividendes.

Biocorp Production dividendes tiek izmaksātas EUR.